Best Options Strategy for VKTX
Looking for the best options strategy for Viking Therapeutics (VKTX)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live VKTX option chain right now, and a simple map from your view on VKTX to the strategy that fits it. Model any of them in the calculator before you trade.
About VKTX
Viking Therapeutics (VKTX) is a major company in clinical-stage biotech (obesity and metabolic drugs). Options traders on VKTX tend to watch clinical trial results, GLP-1 and obesity-drug sentiment and buyout speculation, since these can drive large moves in the share price.
VKTX for options traders
Viking Therapeutics is a clinical-stage biotech chasing the obesity and metabolic-disease market, and that binary, data-dependent business model is exactly why its options carry rich implied volatility. With no mature revenue base to anchor the stock, the share price hinges on a handful of make-or-break events: readouts from GLP-1 and other weight-loss trials, the broader wave of sentiment around obesity drugs, and recurring speculation that a larger pharma player could acquire it. IV therefore sits structurally high and tends to ramp into scheduled trial data, then collapse once results are digested. Options activity concentrates in near-dated expirations around those catalysts, where volume and open interest can swell dramatically.
Because premium is so inflated, some traders lean toward selling it — iron condors, short strangles, or covered calls in calmer windows aim to harvest theta while IV is elevated, though the ever-present threat of a gap on trial news makes naked short structures genuinely dangerous here. Others take the opposite side, buying long calls, debit spreads, or straddles to position for a binary readout or a buyout headline, accepting steep premium and sharp post-event IV crush as the cost of a lottery-style payoff. The key caveat is gap risk: a single overnight data release can move the stock far beyond what any smooth model implies, so defined-risk spreads and modest position sizing are common ways to keep a losing trial from becoming catastrophic.
Today's top-scoring strategy for VKTX
Our engine ranks defined-risk strategies on the live VKTX chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | CALL | $95 | $9.14 |
| Sell | 2× | CALL | $100 | $6.44 |
| Buy | 1× | CALL | $105 | $4.37 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Strategy analysis
Greeks vs price
Price × volatility (today)
| −30% | −15% | IV | +15% | +30% | |
|---|---|---|---|---|---|
| $125 | −$49 | −$41 | −$37 | −$34 | −$33 |
| $120 | −$37 | −$30 | −$27 | −$26 | −$27 |
| $115 | −$19 | −$16 | −$17 | −$19 | −$22 |
| $110 | $2 | −$3 | −$8 | −$13 | −$17 |
| $105 | $20 | $8 | −$1 | −$9 | −$14 |
| $100 | $26 | $11 | $0 | −$8 | −$14 |
| $95 | $16 | $4 | −$4 | −$11 | −$17 |
| $90 | −$8 | −$11 | −$15 | −$19 | −$22 |
| $85 | −$33 | −$29 | −$28 | −$29 | −$30 |
| $80 | −$51 | −$45 | −$41 | −$39 | −$38 |
| $75 | −$60 | −$56 | −$52 | −$49 | −$47 |
Illustrative example at VKTX's latest available price, computed with the same engine as the tool. Live option fills and the real IV skew refresh during US market hours.
Implied volatility
VKTX typically trades with elevated implied volatility, so its options carry richer premiums. Implied volatility drives option prices, so it is worth checking the live chain before you trade.
VKTX insider trading activity (SEC Form 4)
Open-market insider transactions at VKTX over roughly the last six months, from SEC Form 4 filings. Open-market buys are the rarer, more telling signal — routine selling under pre-arranged plans is common, so read a net-selling figure with that in mind.
| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| Lian Brian | Sell | 148,517 | $4.9M | 2026-07-29 |
| Mancini Marianna | Sell | 18,217 | $610K | 2026-07-29 |
| ZANTE GREG | Sell | 21,217 | $710K | 2026-07-29 |
| Aubuchon Neil William | Buy | 4,475 | $150K | 2026-03-10 |
Source: SEC Form 4 filings via Finnhub. Open-market purchases (P) and sales (S) only — grants, option exercises, gifts and tax withholding are excluded. Informational context, not investment advice.
Earnings & IV crush
VKTX's next earnings report is due around October 28, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
Key figures
- Market cap
- $4.0B
- Beta (vs market)
- 0.69
- 52-week range
- $22.96–$43.15
- Short interest
- 20.2% of float · 11.7 days to cover
With 20.2% of VKTX's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
How to choose an options strategy for VKTX
Start with your outlook on VKTX, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while VKTX stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →⧉ Embed this free calculator on your site →
How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open VKTX in the free calculator →
Frequently asked questions
What is the best options strategy for VKTX?
It depends on your outlook. Bullish traders often use a long call or bull call spread on VKTX; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are VKTX options liquid enough to trade?
Viking Therapeutics (VKTX) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade VKTX options?
Buying a single VKTX call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade VKTX or any security. Do your own research.
What does Viking Therapeutics do?
Viking Therapeutics (VKTX) operates in the Biotechnology industry. The "About Viking Therapeutics" section above gives a fuller picture of what the company does and how it earns money.
Does Viking Therapeutics pay a dividend?
We don't show a confirmed dividend yield for Viking Therapeutics here, so treat it as uncertain: before writing calls, check its current dividend and ex-dividend date with your broker — an approaching ex-dividend date can trigger early assignment on in-the-money short calls.
When does Viking Therapeutics next report earnings?
Viking Therapeutics's next earnings are expected around October 28, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.
Tickers related to VKTX
Comparing VKTX with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, 92121, United States
- Industry
- Biotechnology
- Employees
- 65
- CEO
- Dr. Brian Lian Ph.D.
- Phone
- 858 704 4660
- Website
- www.vikingtherapeutics.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.